What do I do if the protocol I want to use is not on eviQ?
If you have a protocol that you would like developed on eviQ, please submit your request by completing the Submit a protocol form.
Currently, the protocol submission page is specific to drug treatment protocols. Other content area submission pages are coming soon. Meanwhile, please email us for other content area submissions.
Note: You will need to be registered and logged in to eviQ to access the form. Please register at the Login and registrations page.
What is the process after I make a protocol submission to eviQ?
The eviQ Data Governance Framework provides an overview of the process for a protocol after it has been submitted for inclusion on eviQ.
How can I know what the status of a protocol or document is on eviQ?
Once the protocol is open, locate the status bar at the top of the protocol. For protocols which are currently under review, discontinued or superseded, this is listed in the title.
What is a superseded protocol?
When new evidence shows that a particular treatment is superior and preferred to the current published treatment protocol, it may be decided following discussion and consensus by the relevant eviQ reference committee that a protocol be superseded. Superseded protocols are still available in their entirety on the eviQ website, as they may still be appropriate for use in certain populations. 'SUPERSEDED' appears in the protocol title and the reason for superseding appears at the top of the protocol.
What is a discontinued protocol?
When a protocol is no longer in use, deemed less efficacious or excessively toxic than alternative treatments, a protocol may be discontinued following discussion and consensus decision by the relevant eviQ reference committee. 'DISCONTINUED' will appear in the title of the protocol and the protocol content will no longer be available on the eviQ website. Information about the history, rationale for discontinuation and related references will still be made available.
When does a protocol or document version number increase?
Protocol or document version number increases when a notable change to a section is carried out. All changes are noted in the History section found by clicking on the Calendar icon at the top right of each protocol page.
How often is a protocol reviewed?
All eviQ treatment protocols are periodically reviewed every one, two or five years to ensure content is based on the latest rigorous evidence. Protocols are stratified into three groups according the following criteria:
Group 1: Annual review
Protocols to undergo a thorough review at 12 months
Protocols for which there are newer drugs with less experience of toxicity effects.
Group 2: Two yearly review
Protocols to undergo review at 2 years from approval date, unless information becomes available that indicates a review is required before this time
Protocols for which there have been significant changes or updates in the literature and/or in clinical practice i.e. for protocols with:
- new evidence
- expansion of patient population through changes to the PBS/TGA
- safety alerts.
Group 3: Five yearly review
Protocols to undergo review at 5 years, unless information becomes available that indicates a review is required before this time
Protocols for which there have been no changes or updates in the literature or in clinical practice i.e. for protocols:
- that have been prescribed for many years where a dose change is unlikely
- where the evidence is supported by systematic reviews
- without safety alerts.
How do I reference eviQ?
eviQ recommends that you use the Harvard AGPS referencing style to reference the eviQ website or specific eviQ content.
To cite the eviQ website as a whole:
Author (the person or organisation responsible for the site) Year (that the site was created or last revised), name and place of the sponsor of the source, viewed Day Month Year,<URL>. e.g. eviQ Cancer Treatments Online 2017, Cancer Institute NSW, viewed 7 March 2017, https://www.eviq.org.au/
To cite a page on the eviQ website:
Title Year, version number (if applicable), description of document (if applicable), name and place of the sponsor of the source, viewed Day Month Year,<URL either full location details or just the main site details> e.g.Clinical resource: Asparaginase 2017 V.2, eviQ Cancer Treatments Online, Cancer Institute NSW, viewed 24th August 2017, eviq.org.au/p/918
What is Tall Man lettering and how is it used on eviQ?
Throughout eviQ some chemotherapy drug names have been modified using Tall Man lettering. Medication names that look or sound alike (LASA) have been identified as a common cause of medication errors, some of which caused considerable patient harm. Tall Man lettering uses a combination of lower and upper case letters to highlight the differences between look alike and sound alike drug names e.g. DOXOrubicin and DAUNOrubicin, helping to make them more easily distinguishable. Tall Man lettering aims to reduces the risk of error by warning health care professionals about the possibility of confusing a particular medicine name and by helping health professionals to select the right product in electronic systems or from shelves.
The Australian Commission on Safety and Quality in Health Care (the Commission) supports the use of Tall Man lettering as part of a multi-faceted program to reduce the risks associated with confusable drug names. eviQ aligns with the National Tall Man Lettering List developed by the Australian Commission on Safety and Quality in Health Care.
How do I access the patient information?
On each protocol, click the patient icon in the top bar to open to the associated patient sheet. You can also access the patient information sheets by clicking on the patient and carers menu.